Advanced searches left 3/3

Metastatic Adenocarcinoma Primary - Europe PMC

Summarized by Plex Scholar
Last Updated: 06 February 2022

* If you want to update the article please login/register

MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).

Background In 80 percent of patients with metastatic pancreatic duct carcinoma adenocarcinoma, the new standard therapy is a systemic therapy consisting of at least doublet-chemotherapy for fit patients. Palliative low-dose radiotherapy is a well-established local treatment strategy, but there is some evidence for a reduced and longer pain response after a dose-intensified radiotherapy of the primary pancreatic cancer. High radiation doses can be delivered in a few fractions, minimizing chemotherapy-free intervals. In a prospective trial, we want to investigate the effect of SBRT on pain control in patients with mPDAC. Methods This is a prospective, double-arm, placebo controlled, international multicenter research examining the additional benefit of MR-guided adaptive SBRT of the pPca embedded between standard care-chemotherapy cycles for pain relief and prevention of pain in patients with mPDAC. Discussion An unsatisfied clinical need is a long-term monitoring of pain symptoms in patients with mPDAC. Patients with mPDAC may benefit from a locally administered SBRT for mPCa treatment, resulting in a more comfortable safe toxicity profile and an improvement in quality-of-life. We hypothesize that patients with mPDAC will benefit from a mPDAC-guided SBRT's results on a durable pain control with a robust safe toxicity profile that leads to an improvement in quality-of-life.

Source link: https://europepmc.org/article/MED/35078490


A Case of Metastatic Non-small Cell Lung Adenocarcinoma and Metachronous Primary Hepatocellular Carcinoma.

Multiple primary malignant neoplasms are typically defined as the co-existence of primary neoplasms of distinct histology in the same individual. Patients with lung cancer are at a greater risk of experiencing a second malignancy in comparison to the general population. However, non-small cell lung adenocarcinoma and primary hepatocellular carcinoma are not described in the literature, but it is not clear that coexistence of non-small cell lung adenocarcinoma and primary hepatocellular carcinoma is missing in the literature.

Source link: https://europepmc.org/article/MED/35004008


Utility of mass spectrometry and artificial intelligence for differentiating primary lung adenocarcinoma and colorectal metastatic pulmonary tumor.

This review investigated the effectiveness of MS and artificial intelligence in detecting primary lung adenocarcinoma and colorectal metastatic pulmonary tumors. Methods Pulmonary samples from 40 patients who underwent pulmonary resection for PLAC or pulmonary metastases originating from colorectal metastatic pulmonary tumor metastases were obtained and analyzed retrospectively by probe electrospray ionization-MS. To determine the effectiveness of each combination, a variety of colorectal metastatic pulmonary tumor was used. Conclusions MS combined with an AI system achieved excellent results not only for distinguishing cancer from normal tissue, but also between PLAC and CRMPT with a short working time.

Source link: https://europepmc.org/article/MED/34812577

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions